Selpercatinib Approved for Metastatic MTC

In September, selpercatinib (also known as LOXO) was approved in England (Cancer Drugs Fund) and Scotland (Interim Basis) for use in metastatic RET-mutation medullary thyroid cancer (MTC) as well as other RET-fusion positive thyroid cancers.